On Friday, Century Therapeutics Inc (NASDAQ: IPSC) opened lower -2.68% from the last session, before settling in for the closing price of $0.57. Price fluctuations for IPSC have ranged from $0.34 to $3.46 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 27.56%. Company’s average yearly earnings per share was noted 70.01% at the time writing. With a float of $40.59 million, this company’s outstanding shares have now reached $86.15 million.
Let’s determine the extent of company efficiency that accounts for 150 employees. In terms of profitability, gross margin is -3.78%, operating margin of -29.1%, and the pretax margin is -17.54%.
Century Therapeutics Inc (IPSC) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Century Therapeutics Inc is 52.92%, while institutional ownership is 28.86%. The most recent insider transaction that took place on May 16 ’25, was worth 16,135. In this transaction President and CEO of this company sold 29,552 shares at a rate of $0.55, taking the stock ownership to the 1,682,258 shares. Before that another transaction happened on May 16 ’25, when Company’s Officer proposed sale 29,552 for $0.55, making the entire transaction worth $16,138.
Century Therapeutics Inc (IPSC) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 70.01% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.86% during the next five years compared to 18.46% growth over the previous five years of trading.
Century Therapeutics Inc (NASDAQ: IPSC) Trading Performance Indicators
Check out the current performance indicators for Century Therapeutics Inc (IPSC). In the past quarter, the stock posted a quick ratio of 11.70. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.28, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.32 in one year’s time.
Technical Analysis of Century Therapeutics Inc (IPSC)
Looking closely at Century Therapeutics Inc (NASDAQ: IPSC), its last 5-days average volume was 0.8 million, which is a jump from its year-to-date volume of 0.57 million. As of the previous 9 days, the stock’s Stochastic %D was 59.92%. Additionally, its Average True Range was 0.05.
During the past 100 days, Century Therapeutics Inc’s (IPSC) raw stochastic average was set at 25.74%, which indicates a significant decrease from 52.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.25% in the past 14 days, which was higher than the 68.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5231, while its 200-day Moving Average is $1.0720. However, in the short run, Century Therapeutics Inc’s stock first resistance to watch stands at $0.5851. Second resistance stands at $0.6115. The third major resistance level sits at $0.6290. If the price goes on to break the first support level at $0.5412, it is likely to go to the next support level at $0.5237. Should the price break the second support level, the third support level stands at $0.4973.
Century Therapeutics Inc (NASDAQ: IPSC) Key Stats
There are currently 86,159K shares outstanding in the company with a market cap of 48.15 million. Presently, the company’s annual sales total 6,590 K according to its annual income of -126,570 K. Last quarter, the company’s sales amounted to 109,160 K and its income totaled 76,560 K.
